Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers

Improving patient outcome by personalized therapy involves a thorough understanding of an agent’s mechanism of action. β-Lapachone (clinical forms, Arq501/Arq761) has been developed to exploit dramatic cancer-specific elevations in the phase II detoxifying enzyme, NAD(P)H:quinone oxidoreductase (NQO...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Bey, Erik A., Reinicke, Kathryn E., Srougi, Melissa C., Varnes, Marie, Anderson, Vernon, Pink, John J., Li, Long Shan, Patel, Malina, Cao, Lifen, Moore, Zachary, Rommel, Amy, Boatman, Michael, Lewis, Cheryl, Euhus, David M., Bornmann, William G., Buchsbaum, Donald J., Spitz, Douglas R., Gao, Jinming, Boothman, David A.
Формат: Artigo
Язык:Inglês
Опубликовано: 2013
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3807805/
https://ncbi.nlm.nih.gov/pubmed/23883585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-12-0962
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы